

# Michael Grabner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5516340/publications.pdf>

Version: 2024-02-01

28  
papers

420  
citations

840585

11  
h-index

752573

20  
g-index

29  
all docs

29  
docs citations

29  
times ranked

667  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 920-929.	2.2	59
2	Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. <i>Atherosclerosis</i> , 2014, 235, 585-591.	0.4	53
3	Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets. <i>Diabetes Research and Clinical Practice</i> , 2016, 121, 17-26.	1.1	50
4	Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment. <i>Current Medical Research and Opinion</i> , 2018, 34, 995-1003.	0.9	41
5	Clinical and Economic Outcomes Among Patients With Diabetes Mellitus Initiating Insulin Glargine Pen Versus Vial. <i>Postgraduate Medicine</i> , 2013, 125, 204-213.	0.9	30
6	The INITIATOR Study: Pilot Data on Real-World Clinical and Economic Outcomes in US Patients with Type 2 Diabetes Initiating Injectable Therapy. <i>Advances in Therapy</i> , 2013, 30, 1128-1140.	1.3	22
7	Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide <sc>B</sc>: 6-month follow-up from <sc>US real-world</sc> data. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 106-115.	2.2	20
8	A real-world study of treatment patterns and outcomes in <sc>US</sc> managed-care patients with type 2 Diabetes initiating injectable therapies. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 375-386.	2.2	18
9	Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis. <i>Arthritis Research and Therapy</i> , 2017, 19, 92.	1.6	17
10	Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels. <i>Atherosclerosis</i> , 2014, 237, 790-797.	0.4	16
11	Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000884.	1.2	16
12	Cost-Effectiveness of a Proteomic Test for Preterm Birth Prediction. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 809-820.	0.7	11
13	Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2015, 21, 1204-1212.	0.5	10
14	Primary care physician perspectives on basal insulin initiation and maintenance in patients with type 2 diabetes mellitus. <i>Primary Care Diabetes</i> , 2018, 12, 155-162.	0.9	10
15	Cost Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level. <i>American Journal of Cardiology</i> , 2017, 119, 404-409.	0.7	9
16	Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism. <i>Journal of Sexual Medicine</i> , 2018, 15, 148-158.	0.3	9
17	Data Integration to Improve Real-world Health Outcomes Research for Non-Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration. <i>JMIR Cancer</i> , 2021, 7, e23161.	0.9	6
18	Identifying inadequate response among patients with ankylosing spondylitis and psoriatic arthritis prescribed advanced therapy in a real-world, commercially insured adult population in the USA. <i>Clinical Rheumatology</i> , 2022, 41, 2863-2874.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results. <i>Clinical Therapeutics</i> , 2020, 42, 2184-2195.	1.1	4
20	&lt;p&gt;Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States&lt;/p&gt;. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 1023-1033.	1.1	4
21	Prevalence of Renal Impairment in a US Commercially Insured Rheumatoid Arthritis Population: A Retrospective Analysis. <i>Rheumatology and Therapy</i> , 2021, 8, 1383-1391.	1.1	3
22	Clinical Characteristics, Health Care Utilization and Costs Among Men with Primary or Secondary Hypogonadism in a US Commercially Insured Population. <i>Journal of Sexual Medicine</i> , 2017, 14, 88-97.	0.3	2
23	Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, , 1-14.	0.5	2
24	Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2417-2429.	0.8	2
25	<p>Reliability of Conclusions from Early Analyses of Real-World Data for Newly Approved Drugs in Advanced Gastric Cancer in the United States</p>. <i>Journal of Pragmatic and Observational Research</i> , 2020, Volume 11, 27-43.	1.1	1
26	&lt;p&gt;Occurrence and Characteristics of Hospitalizations During First-Line Chemotherapy Among Individuals with Metastatic Colorectal Cancer&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 1535-1541.	0.9	0
27	Comparative Effectiveness of Persistent Use of a Name-Brand Levothyroxine (Synthroid®) vs. Persistent Use of Generic Levothyroxine on TSH Goal Achievement: A Retrospective Study Among Patients with Hypothyroidism in a Managed Care Setting. <i>Advances in Therapy</i> , 2022, 39, 779-795.	1.3	0
28	Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States. <i>Clinical Therapeutics</i> , 2022, , .	1.1	0